1 day Ago By Defense World Staff
Bank of New York Mellon Corp lifted its holdings in shares of Travere Therapeutics, Inc. ( NASDAQ:TVTX – Free Report ) by 18.3% during the 2nd quarter, according to the company in its most recent filing with the SEC.
The fund owned 264,816 shares of the company’s stock after purchasing an additional 41,048 shares during the period. Bank of New York Mellon Corp owned about 0.35% of Travere Therapeutics worth $2,177,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new position in shares of Travere Therapeutics in the first quarter worth about $32,000. China Universal Asset Management Co.
Ltd. increased its stake in Travere Therapeutics by 68.6% in the 1st quarter.
China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock worth $113,000 after purchasing an additional 5,962 shares during the period.
Dynamic Technology Lab Private Ltd bought a new stake in Travere Therapeutics in the fourth quarter valued at approximately $137,000. SG Americas Securities LLC purchased a new stake in shares of Travere Therapeutics during the second quarter valued at approximately $139,000. Finally, ProShare Advisors LLC grew its holdings in shares of Travere Therapeutics by 9.
2% in the first quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after purchasing an additional 1,557 shares during the last quarter. Travere Therapeutics Price Performance NASDAQ TVTX opened at $14.
40 on Wednesday. The firm’s fifty day simple moving average is $9.79 and its two-hundred day simple moving average is $8.
04. The company has a current ratio of 3.04, a quick ratio of 2.
99 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc.
has a 12-month low of $5.12 and a 12-month high of $14.79.
The firm has a market capitalization of $1.10 billion, a P/E ratio of -6.86 and a beta of 0.
71. Insider Buying and Selling In related news, CFO Christopher R. Cline sold 2,490 shares of the firm’s stock in a transaction dated Monday, September 9th.
The stock was sold at an average price of $11.52, for a total transaction of $28,684.80.
Following the sale, the chief financial officer now directly owns 74,595 shares of the company’s stock, valued at $859,334.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink .
In other news, CFO Christopher R. Cline sold 2,490 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.
52, for a total value of $28,684.80. Following the transaction, the chief financial officer now owns 74,595 shares in the company, valued at $859,334.
40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Also, CEO Eric M.
Dube sold 21,125 shares of Travere Therapeutics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.
00. Following the transaction, the chief executive officer now owns 361,975 shares in the company, valued at approximately $4,169,952. The disclosure for this sale can be found here .
Insiders have sold a total of 30,707 shares of company stock valued at $352,712 over the last ninety days. Company insiders own 3.75% of the company’s stock.
Analyst Upgrades and Downgrades TVTX has been the subject of several recent analyst reports. Citigroup upped their price objective on shares of Travere Therapeutics from $14.00 to $23.
00 and gave the company a “buy” rating in a research note on Friday, September 6th. Wedbush increased their price objective on Travere Therapeutics from $13.00 to $16.
00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Bank of America boosted their target price on Travere Therapeutics from $18.00 to $19.
00 and gave the company a “buy” rating in a research note on Friday, September 6th. HC Wainwright upped their target price on Travere Therapeutics from $20.00 to $23.
00 and gave the company a “buy” rating in a report on Friday, September 6th. Finally, Piper Sandler lifted their price target on shares of Travere Therapeutics from $11.00 to $12.
00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.
58. Check Out Our Latest Report on Travere Therapeutics About Travere Therapeutics ( Free Report ) Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading Five stocks we like better than Travere Therapeutics What is a Secondary Public Offering? What Investors Need to Know Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? What to Know About Investing in Penny Stocks Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Industrial Products Stocks Investing Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. ( NASDAQ:TVTX – Free Report ).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
